Abstract:Although synthetic glucocorticoids (GCs) are commonly used to treat autoimmune and other diseases, GC induced osteoporosis (GIOP) which accounts for 25% of the adverse reactions, causes fractures in 30–50% of patients, and markedly decreases their quality of life. In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) published the revised guidelines for the management and treatment of steroid-induced osteoporosis, providing the treatment criteria based on scores of risk factors, including previous fractures, age, GC doses, and bone mineral density, for patients aged ≥18 years who are receiving GC therapy or scheduled to receive GC therapy for ≥3 months.

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to solve the problems of management and treatment of glucocorticoid - induced osteoporosis (GIOP). Specifically, the goals of the paper are: 1. **Formulate management and treatment guidelines for GIOP**: Through systematic review and consensus meetings, using the Delphi method, to provide the best suggestions for the management and treatment of GIOP. 2. **Evaluate risk factors and propose preventive measures**: Identify the risk factors of GIOP, and based on these factors, put forward corresponding management and treatment suggestions to prevent fractures and other complications. 3. **Recommend effective drug treatment regimens**: According to the principles of evidence - based medicine, recommend effective drugs for increasing bone density and preventing fractures, including bisphosphonates, anti - RANKL antibodies, teriparatide, eldecalcitol, etc. 4. **Improve the quality of life of patients**: Given that GIOP may cause fractures in 30 - 50% of patients and seriously affect the quality of life, the guidelines emphasize the importance of early intervention and comprehensive management. ### Background information Glucocorticoids (GCs) are widely used in the treatment of autoimmune diseases and other diseases, but one of their side effects is to cause osteoporosis (GIOP), which is especially common in patients with long - term use of GCs. GIOP not only causes fractures but also significantly reduces the quality of life of patients. Therefore, the Japanese Society for Bone and Mineral Research (JSBMR) first released guidelines on the management and treatment of steroid - induced osteoporosis in 2004 and revised them in 2004. With the development of anti - osteoporosis drugs and the accumulation of more evidence, JSBMR has revised the guidelines again to reflect the latest scientific progress and clinical practice. ### Main content The paper prepared 17 clinical questions (CQs) through systematic review and expert consensus, covering the epidemiology, clinical features, pathological mechanisms, treatment initiation criteria, drug efficacy, and management and treatment of special populations (such as children, the elderly, and women of childbearing age) of GIOP. Each CQ has been subject to detailed literature search, screening, and evaluation, and evidence grading and recommendation strength assessment are carried out according to the GRADE method. ### Conclusion The 2023 GIOP management and treatment guidelines, based on the latest scientific evidence and expert opinions, provide comprehensive management and treatment suggestions. The guidelines emphasize the importance of early intervention and multidisciplinary cooperation to minimize the impact of GIOP on patients and improve their quality of life. ### Keywords Glucocorticoid, Osteoporosis, Glucocorticoid - induced Osteoporosis, Fracture, Treatment --- From the above summary, it can be seen that the main purpose of this paper is to provide the latest and scientific guidance for the management and treatment of GIOP through systematic evidence assessment and expert consensus, thereby improving the prognosis and quality of life of patients.

The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis

[Glucocorticoid and Bone. The changes of Japanese and foreign guidelines for the management of glucocorticoid-induced osteoporosis]

The epidemiological investigation on glucocorticoid-induced osteoporosis

Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020)

Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis

Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update

[Secondary osteoporosis. Guidelines for glucocorticoid-induced osteoporosis]

Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis in pediatrics

Update on the Treatment of Glucocorticoid-Induced Osteoporosis

When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

[Prophylaxis and therapy of the glucocorticoid-induced osteoporosis - a review of recent guidelines]

A Survey to Glucocorticoid Induced Oseoporosis Management in Rheumatologists in China

Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment

Development and Comparison of Treatment Decision Tools for Glucocorticoid-Induced Osteoporosis

Glucocorticoid-Induced Osteoporosis: Increased Awareness as a Management Strategy for Prevention of this Complication in Patients with Systemic Autoimmune Rheumatic Disease

Low-dose glucocorticoid increase the risk of fracture in postmenopausal women with low bone mass: a retrospective cohort study

Effects of iguratimod on glucocorticoid-induced disorder of bone metabolism in vitro

Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

Glucocorticoids and bone: local effects and systemic implications

Approach to the Pediatric Patient With Glucocorticoid-Induced Osteoporosis

Exercise effects on glucocorticoid-induced bone loss in adults: a systematic review and meta-analysis